Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
09 October 2023 - 11:15PM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company focused on delivering innovative immunology therapeutics,
today announced it will host a virtual R&D event for the
investment community on rosnilimab, a PD-1 agonist antibody, at
4:15pm ET/1:15pm PT on Wednesday, Oct. 25.
Independent medical experts and members of Anaptys senior
management will discuss:
- PD-1 biology and rosnilimab’s mechanism of action
- Rheumatoid arthritis: Unmet need, market opportunity and Phase
2 development plan which initiated in August
- Second indication (to be unveiled during this webcast): Unmet
need, market opportunity and Phase 2 development plan which will
initiate in Q4 2023
The approximately 90-minute event will be followed by a Q&A
session with Anaptys senior management.
A live webcast of the presentation will be available on the
investor section of the Anaptys website at
https://ir.anaptysbio.com/events. A replay of the webcast,
including supporting materials, will be available following the
event.
About rosnilimab
Rosnilimab is a novel PD-1 checkpoint agonist antibody that
reduces overactive T cell inflammation. It has two distinct
mechanisms of action, depletion and agonism, prevalent both in
inflamed tissue and the periphery, targeting PD-1+ T cells broadly
impacting multiple drivers of disease pathogenesis. To date,
rosnilimab has been well-tolerated, with no dose-limiting
toxicities and no serious treatment-related adverse events
reported.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on
delivering innovative immunology therapeutics. It is developing
immune cell modulators, including two checkpoint agonists in
clinical-stage development, for autoimmune and inflammatory
disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the
treatment of moderate-to-severe rheumatoid arthritis; and ANB032,
its BTLA agonist, in a Phase 2b trial for the treatment of
moderate-to-severe atopic dermatitis. Its preclinical immune cell
modulator portfolio includes ANB033, an anti-CD122 antagonist
antibody for the treatment of autoimmune and inflammatory diseases.
In addition, Anaptys has developed two cytokine antagonists
available for out-licensing: imsidolimab, an anti-IL-36R
antagonist, in Phase 3 for the treatment of generalized pustular
psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the
treatment of respiratory disorders that is Phase 2/3 ready. Anaptys
has also discovered multiple therapeutic antibodies licensed to GSK
in a financial collaboration for immune-oncology, including an
anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)), an
anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an
anti-LAG-3 antagonist antibody (GSK4074386).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to: the timing of initiation of the company’s clinical
trials, including rosnilimab’s clinical trial in a second
indication; and the company’s ability to find a licensing partner
for imsidolimab or etokimab and the timing of any such transaction.
Statements including words such as “plan,” “continue,” “expect,” or
“ongoing” and statements in the future tense are forward-looking
statements. These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause its results to differ
materially from those expressed or implied by such forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that may cause the company’s actual activities or
results to differ significantly from those expressed in any
forward-looking statement, including risks and uncertainties
related to the company’s ability to advance its product candidates,
obtain regulatory approval of and ultimately commercialize its
product candidates, the timing and results of preclinical and
clinical trials, the company’s ability to fund development
activities and achieve development goals, the company’s ability to
protect intellectual property and other risks and uncertainties
described under the heading “Risk Factors” in documents the company
files from time to time with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date of this press release, and the company undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Contact:
Nick MontemaranoSenior Director, Investor Relations and
Strategic Communications 858.732.0178investors@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2024 to May 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From May 2023 to May 2024